Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant ...
This story was updated on 18 April 2017 to correct an error. Cerebrospinal fluid biomarkers of Alzheimer’s disease have transformed clinical research, but ...
The Chosun Ilbo on MSN
Dried blood samples match CSF accuracy in Alzheimer's detection
A technology that diagnoses various diseases, including Alzheimer’s and Parkinson’s, using just a few drops of blood from a ...
In a recent study published in Jama Network, researchers investigated the impact of coronavirus disease 2019 (COVID-19) on biomarkers in the cerebrospinal fluid (CSF). Study: Viral Antigen and ...
Director, Molecular Microbiology Assistant Director, Clinical Microbiology and Immunoserology Laboratories Nationwide Children's Hospital Associate Professor - Clinical, College of Medicine, The Ohio ...
Sequencing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) improved diagnosis, decision-making, and clinical care in pediatric and adolescent and young adult (AYA) patients with ...
Hypogammaglobulinemia in pts receiving rituximab immunotherapy and the impact of rituximab maintenance. Correlation of tumoricidal activity of lenalidomide against hematologic tumor cells with cyclin ...
What a difference a year can make. At the 2011 Alzheimer’s Association International Conference in Paris, France, leading scientists in the CSF Alzheimer’s biomarker field met to tackle the vexing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback